Article ISI
ANNALS OF ONCOLOGY  (2021)

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase III KEYNOTE-826 study

Colombo, N.; Dubot, C.; Lorusso, D.; Caceres, V.; Hasegawa, K.; Shapira-Frommer, R.; Tewari, K. S.; Salman, P.; Hoyos, E.; Yanez, E.; Gumus, M.; De Mendoza, M. Olivera Hurtado; Samouelian, V.; Castonguay, V.; Arkhipov, A.; et. al.